- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02284789
Colorado Adult Joint Assessment Scale (CAJAS) Validation (CAJAS)
December 2, 2015 updated by: Bayer
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
To obtain evidence of content validity and reliability of the Colorado Adult Joint Assessment Scale (CAJAS), a clinician-reported outcome (ClinRO) measure, as adapted for use in a population of adults with moderate to severe hemophilia A treated with coagulation factor VIII (FVIII) therapy as secondary prophylaxis or episodic treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Orange, California, United States, 92868
-
-
Colorado
-
Aurora, Colorado, United States, 80045
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
-
-
Oregon
-
Portland, Oregon, United States, 97239
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male, 18 to 50 years of age
- Diagnosis of moderate to severe hemophilia A (documented <1-2% Factor VIII Concentration [FVIII:C])
- Willing to maintain current FVIII treatment regimen, whether prophylactic or on-demand, for the duration of the study
Exclusion Criteria:
- Routine need for wheelchair or routine need for two canes or crutches
- Diagnosis of another bleeding disorder such as von Willebrand Disease
- Known event that would interfere with the scheduled CAJAS evaluations (e.g., elective joint surgery, vacation)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: CAJAS evaluation
|
Physical evaluation of 6 joints, ankles, knees and elbows
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Colorado Adult Joint Assessment Score (CAJAS)
Time Frame: Up to 25 days
|
Up to 25 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
November 4, 2014
First Submitted That Met QC Criteria
November 4, 2014
First Posted (Estimate)
November 6, 2014
Study Record Updates
Last Update Posted (Estimate)
December 3, 2015
Last Update Submitted That Met QC Criteria
December 2, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17819
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia A
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
GWT-TUD GmbHHannover Medical School; Hoffmann-La RocheCompleted
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
Hoffmann-La RocheActive, not recruitingSevere Hemophilia A | Moderate Hemophilia ABrazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
-
JW PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A Without InhibitorKorea, Republic of
-
PfizerCompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
BioMarin PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A With Anti Factor VIIIUnited States, United Kingdom, Taiwan, Israel, Korea, Republic of, South Africa, Brazil, Italy, Germany
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
BayerCompletedHemophilia A; Hemophilia BIsrael
Clinical Trials on Colorado Adult Joint Assessment Evaluation
-
Ankara Yildirim Beyazıt UniversityCompletedType 2 Diabetes Mellitus | BalanceTurkey
-
Ahram Canadian UniversityCompleted
-
University Hospital, BordeauxRecruitingMultiple SclerosisFrance
-
Centre Psychothérapique de NancyConseil Départemental, Protection Maternelle Infantile :PMI, France; Agence... and other collaboratorsActive, not recruitingDevelopment, Infant | Perinatal DisorderFrance
-
Hospital General de Chihuahua - Dr. Salvador Zubirán...Faculty of Medicine and Biomedical Sciences, Autonomous University of ChihuahuaRecruiting
-
University Hospital, BordeauxRoche Pharma AGRecruitingMultiple Sclerosis, Primary ProgressiveFrance
-
Universidad de GranadaUnknownChronic Obstructive Pulmonary DiseaseSpain
-
Istituto Ortopedico RizzoliUnknown
-
Universitat Internacional de CatalunyaFundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaCompletedStroke | Cerebrovascular Disorders | Cerebral Infarction | Gait, HemiplegicSpain